946 Results for "

C3

" in MedChemExpress (MCE) Product Catalog:
Products (946)

946 Results for "C3" in MCE Product Catalog:

35
35 Publications Verification
Cat. No.: HY-12481
CAS No.: 1523406-39-4
Purity:  99.74%
Target:  

PI3K Autophagy

Research Areas:  

Cancer

SAR405 is a first-in-class, selective, and ATP-competitive PI3K class III (PIK3C3) isoform Vps34 inhibitor (IC50=1.2 nM; Kd=1.5 nM). SAR405 inhibits autophagy induced either by starvation or by mTOR inhibition. Anticancer activity .
29
29 Cited Publications
Cat. No.: HY-101502A
CAS No.: 1140525-25-2
Purity:  99.82%
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

SB290157 trifluoroacetate is a potent and selective C3a receptor antagonist with an IC50 of 200 nM.
15
15 Cited Publications
Cat. No.: HY-N0376
CAS No.: 551-15-5
Liquiritin, a flavonoid isolated from Glycyrrhiza uralensis, is a potent and competitive AKR1C1 inhibitor with IC50s of 0.62 μM, 0.61 μM, and 3.72μM for AKR1C1, AKR1C2 and AKR1C3, respectively. Liquiritin efficiently inhibits progesterone metabolism mediated by AKR1C1 in vivo . Liquiritin acts as an antioxidant and has neuroprotective, anti-cancer and anti-inflammatory activity .
13
13 Cited Publications
Cat. No.: HY-127105
CAS No.: 1644670-37-0
Purity:  99.93%
Synonyms: LNP023
Iptacopan (LNP023) is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) [3].
13
13 Cited Publications
Cat. No.: HY-127105A
CAS No.: 1646321-63-2
Purity:  99.83%
Synonyms: LNP023 hydrochloride
Iptacopan (LNP023) hydrochloride is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan hydrochloride exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) [3].
10
10 Cited Publications
Cat. No.: HY-15976
CAS No.: 301353-96-8
Target:  

Others

Research Areas:  

Neurological Disease

P7C3 is an orally bioavailable and blood-brain barrier penetrant aminopropyl carbazole, with neuroprotective effects. P7C3 can be used for the research of neurodegenerative diseases, including Parkinson's disease [3].
9
9 Cited Publications
Cat. No.: HY-138161
CAS No.: 2411440-41-8
Purity:  99.59%
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation .
8
8 Cited Publications
Cat. No.: HY-106178
CAS No.: 219639-75-5
Purity:  99.98%
Synonyms: 3D53
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects [3] .
7
7 Cited Publications
Cat. No.: HY-P1717
CAS No.: 1427001-89-5
Synonyms: Cp40
Research Areas:  

Inflammation/Immunology

AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
7
7 Cited Publications
Cat. No.: HY-P1717B
Synonyms: Cp40 acetate
Research Areas:  

Inflammation/Immunology

AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
7
7 Cited Publications
Cat. No.: HY-P1717A
CAS No.: 1789738-04-0
Synonyms: Cp40 TFA
Research Areas:  

Inflammation/Immunology

AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation .
7
7 Cited Publications
Cat. No.: HY-P7863
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rMuComplement C3/C3a; Complement Component C3a; Anaphylatoxin; C3a
Species:  
Source:  
6
6 Cited Publications
Cat. No.: HY-15978
CAS No.: 1235481-90-9
Target:  

Others

Research Areas:  

Neurological Disease

P7C3-A20 is a derivative of P7C3 with potent proneurogenic and neuroprotective activity. P7C3-A20 exerts an antidepressant-like effect. P7C3-A20 can cross the blood-brain barrier and therefore has the potential for brain injury treatment [3].
5
5 Cited Publications
Cat. No.: HY-132295
CAS No.: 2376146-48-2
Purity:  99.96%
Synonyms: ZN-C3
Target:  

Wee1

Research Areas:  

Cancer

Azenosertib (ZN-c3) is a selective, orally active inhibitor for Wee1 inhibitor (IC50=3.9 nM). Azenosertib exhibits antitumor activity .
5
5 Cited Publications
Cat. No.: HY-P7862
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuComplement C3/C3a; Complement Component C3a; C3a; Anaphylatoxin
Species:  
Source:  
4
4 Cited Publications
Cat. No.: HY-103007
CAS No.: 1621175-65-2
Purity:  99.36%
Synonyms: GPR39-C3
Target:  

GPR39

Research Areas:  

Metabolic Disease Endocrinology

TC-G-1008 (GPR39-C3) is a potent and orally available GPR39 agonist with EC50 values of 0.4 and 0.8 nM for rat and human receptors respectively.
3
3 Cited Publications
Cat. No.: HY-P1036
CAS No.: 206645-99-0
Target:  

Complement System

Research Areas:  

Others

Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively [3] .
3
3 Cited Publications
Cat. No.: HY-P1036A
Target:  

Complement System

Research Areas:  

Others

Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively [3].
3
3 Cited Publications
Cat. No.: HY-P2141
CAS No.: 1234510-46-3
Synonyms: TRV027
Research Areas:  

Cardiovascular Disease

TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages β-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R-β-arrestin-1-TRPC3-PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .
3
3 Cited Publications
Cat. No.: HY-P2141A
Research Areas:  

Cardiovascular Disease

TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ?-arrestins while blocking G-protein signaling . TRV120027?TFA induces?acute?catecholamine?secretion?through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the?acute decompensated heart failure (ADHF) treatment .